Total Liabilities Equity - Maat Pharma SA (PAR:MAAT) - Alpha Spread
M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.3 EUR 2.24% Market Closed
Market Cap: 101.4m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Maat Pharma SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Maat Pharma SA
Total Liabilities & Equity Peer Comparison

Comparables:
VLA
NANO
IPH
GNFT
ALERS

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
M
Maat Pharma SA
PAR:MAAT
Total Liabilities & Equity
€42.9m
CAGR 3-Years
21%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Total Liabilities & Equity
€466.6m
CAGR 3-Years
-14%
CAGR 5-Years
13%
CAGR 10-Years
7%
Nanobiotix SA
PAR:NANO
Total Liabilities & Equity
€93.9m
CAGR 3-Years
-11%
CAGR 5-Years
15%
CAGR 10-Years
29%
Innate Pharma SA
PAR:IPH
Total Liabilities & Equity
€151.5m
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
4%
Genfit SA
NASDAQ:GNFT
Total Liabilities & Equity
€173.9m
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
20%
Eurobio Scientific SA
PAR:ALERS
Total Liabilities & Equity
€316.3m
CAGR 3-Years
22%
CAGR 5-Years
35%
CAGR 10-Years
25%

See Also

What is Maat Pharma SA's Total Liabilities & Equity?
Total Liabilities & Equity
42.9m EUR

Based on the financial report for Dec 31, 2023, Maat Pharma SA's Total Liabilities & Equity amounts to 42.9m EUR.

What is Maat Pharma SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
49%

Over the last year, the Total Liabilities & Equity growth was -4%. The average annual Total Liabilities & Equity growth rates for Maat Pharma SA have been 21% over the past three years , 49% over the past five years .

Back to Top